0054-4129 : Cyclophosphamide 25 mg Oral Tablet


NDC: 0054-4129
Labeler: Roxane Laboratories, Inc
Product Type: Human Prescription Drug
Drug Name:  Cyclophosphamide
Dosage Form: Oral Tablet
Application #: ANDA040032
Rev. Date: 


Appearance:


Markings: 54-639
54;639
Shapes:  Round
Colors:  Blue
Size (mm): 9
Segments: * 1

* Segments = the number of equally sized pieces which the pill can be broken into. In this case, a value of 1 indicates a solid pill with no score lines.

54-639<br/>54 639: (0054-4129) Cyclophosphamide 25 mg Oral Tablet by Roxane Laboratories, Inc
The above image is provided by the U.S. National Library of Medicine (NLM) and is not part of the official label.

NDC Package Codes:

  • 0054-4129-25: 100 TABLET IN 1 BOTTLE, PLASTIC (0054‑4129‑25)

Active Ingredients:

  • Cyclophosphamide

Dosage Strength:

  • 25 mg

Inactive Ingredients:

  • Acacia
  • Fd&c Blue No. 1
  • Lactose Monohydrate
  • Magnesium Stearate
  • Cellulose, Microcrystalline
  • Acacia
  • Fd&c Blue No. 1
  • Lactose Monohydrate
  • Magnesium Stearate
  • Microcrystalline Cellulose

Pharmaceutical Classes:

  • Alkylating Activity [MoA]
  • Alkylating Drug [EPC]

Related Products:

Based on records with the same trade name.
  • 0054-4130 Cyclophosphamide 50 mg Oral Tablet by Roxane Laboratories, Inc
  • 0054-0382 Cyclophosphamide 25 mg Oral Capsule by Roxane Laboratories, Inc.
  • 0054-0383 Cyclophosphamide 50 mg Oral Capsule by Roxane Laboratories, Inc.
  • 0781-3233 Cyclophosphamide 500 mg/25ml Intravenous; Oral Injection, Powder, for Solution by Sandoz Inc.
  • 0781-3244 Cyclophosphamide 1 g/50ml Intravenous; Oral Injection, Powder, for Solution by Sandoz Inc.
  • 0781-3255 Cyclophosphamide 2 g/100ml Intravenous; Oral Injection, Powder, for Solution by Sandoz Inc.
  • 10019-935 Cyclophosphamide 500 mg/25ml Intravenous; Oral Injection, Powder, for Solution by Baxter Healthcare Corporation
  • 10019-936 Cyclophosphamide 1 g/50ml Intravenous; Oral Injection, Powder, for Solution by Baxter Healthcare Corporation
  • 10019-937 Cyclophosphamide 2 g/100ml Intravenous; Oral Injection, Powder, for Solution by Baxter Healthcare Corporation
  • 10019-938 Cyclophosphamide 500 mg/25ml Intravenous; Oral Injection, Powder, for Solution by Baxter Healthcare Corporation
  • 10019-939 Cyclophosphamide 1 g/50ml Intravenous; Oral Injection, Powder, for Solution by Baxter Healthcare Corporation
  • 10019-942 Cyclophosphamide 2 g/100ml Intravenous; Oral Injection, Powder, for Solution by Baxter Healthcare Corporation
  • 10019-943 Cyclophosphamide 500 mg/25ml Intravenous; Oral Injection, Powder, for Solution by Baxter Healthcare Corporation
  • 10019-944 Cyclophosphamide 1 g/50ml Intravenous; Oral Injection, Powder, for Solution by Baxter Healthcare Corporation
  • 10019-945 Cyclophosphamide 2 g/100ml Intravenous; Oral Injection, Powder, for Solution by Baxter Healthcare Corporation
  • 10019-955 Cyclophosphamide 500 mg/25ml Intravenous; Oral Injection, Powder, for Solution by Baxter Healthcare Corporation
  • 10019-956 Cyclophosphamide 1 g/50ml Intravenous; Oral Injection, Powder, for Solution by Baxter Healthcare Corporation
  • 10019-957 Cyclophosphamide 2 g/100ml Intravenous; Oral Injection, Powder, for Solution by Baxter Healthcare Corporation
  • 10019-982 Cyclophosphamide 25 mg Oral Tablet by Baxter Healthcare Corporation
  • 10019-984 Cyclophosphamide 50 mg Oral Tablet by Baxter Healthcare Corporation
  • More related products ...

NDC QR Code

Scan the QR code below to easily reference this data in the future:

NDC 0054-4129 QR Code

< Prev: 0054-4120Next: 0054-4130 >

Related Discussions:

greyhound cyclophosphamide with pirixicam cyl hycl 100 cap
My Greyhound Cut his Foot And He Takes Cyclophosphamide 17 Mg With Pirixicam 11 mg once A Day with food. I Want To Know ...




Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.